Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have earned a consensus rating of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $37.9286.

Several research firms have weighed in on GMAB. Weiss Ratings cut Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Jefferies Financial Group initiated coverage on Genmab A/S in a research note on Tuesday, February 17th. They set a “buy” rating and a $41.50 target price for the company. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. HC Wainwright lowered their target price on Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. Finally, The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd.

Genmab A/S Stock Up 1.2%

GMAB stock opened at $27.04 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. The stock has a market capitalization of $16.86 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.59 and a beta of 0.86. The business’s fifty day moving average price is $27.00 and its two-hundred day moving average price is $29.64. Genmab A/S has a fifty-two week low of $20.23 and a fifty-two week high of $35.43.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC boosted its stake in shares of Genmab A/S by 291.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 616 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares in the last quarter. V Square Quantitative Management LLC bought a new position in shares of Genmab A/S during the first quarter worth about $34,000. NewEdge Advisors LLC raised its position in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after acquiring an additional 1,143 shares during the last quarter. Finally, Brown Brothers Harriman & Co. raised its position in shares of Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after acquiring an additional 780 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.